Effect of Atomoxetine and a standardized behavior therapy on attention deficits in adult ADHD - Atomoxetine and adult ADHD
- Conditions
- Adult Attention Deficit Hyperactivity DisorderMedDRA version: 8.1Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorder
- Registration Number
- EUCTR2006-004073-10-DE
- Lead Sponsor
- niversity of Giessen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
•Actual diagnosis of ADHD according to DSM IV
•Age 18 to 50
•Both sexes
•Declaration of informed consent for all clinical measures
•Normal IQ (Estimated by a short IQ test during the screening)
•Normal ECG findings
•Sufficient knowledge of the German language to follow instructions and training procedure
•In- and out-patients
•Consent to a highly effective birth control method (failure rate less than 1%) for female patients in childbearing years
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
•Other psychiatric disorder according to DSM IV
•Any neurological disorder
•Tachykardia, hyperpiesia or very low blood pressure
•Liver malfunctions
•Contraindication for the usage of Atomoxetine as listed in the companies safety information
•Intake of antibiotics, azol-antimycotics, antihistamines or antiarrhythmics
•History of allergic reaction to Atomoxetine
•Female patients who are pregnant or nursing
•Other medication that affects the central nervous system
•Paticipation in other clinical trials
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method